PMID- 25555492
OWN - NLM
STAT- MEDLINE
DCOM- 20170906
LR  - 20210504
IS  - 1578-1275 (Electronic)
IS  - 0212-6567 (Print)
IS  - 0212-6567 (Linking)
VI  - 47
IP  - 8
DP  - 2015 Oct
TI  - [Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and 
      other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in 
      Spain].
PG  - 505-13
LID - S0212-6567(14)00390-4 [pii]
LID - 10.1016/j.aprim.2014.11.002 [doi]
AB  - OBJECTIVE: To assess the efficiency of the combined therapy with metformin and 
      dapagliflozin, a new oral anti-diabetic drug with an insulin-independent 
      mechanism of action, in the treatment of type-2 diabetes mellitus (T2DM) compared 
      to DPP4 inhibitors, sulphonylureas and thiazolidindiones, also combined with 
      metformin. DESIGN: Cost-effectiveness analysis using a discrete event simulation 
      model based on the results of the available clinical trials and considering 
      patient's entire life as time horizon. SETTING: National Health System 
      perspective. PARTICIPANTS: The model simulated the natural history of 30,000 
      patients with T2DM for each of the options compared. MAIN MEASUREMENTS: 
      Quality-adjusted life-years (QALY) and economic consequences of managing the 
      disease and its complications. The analysis considered direct costs updated to 
      2013. A discount rate of 3% was applied to costs and health outcomes. RESULTS: In 
      the main analysis comparing dapagliflozin with DPP4 inhibitors, dapagliflozin 
      resulted in a treatment option that would provide a slightly higher effectiveness 
      (0.019 QALY) and lower overall associated costs (-euro42). In the additional 
      analyses, dapagliflozin was a cost-effective option compared with sulphonylureas 
      and thiazolidinediones resulting in a cost per QALY gained of euro3,560 and euro2,007, 
      respectively. The univariate and probabilistic sensitivity analyses confirmed the 
      robustness of the results. CONCLUSIONS: The results of the analyses performed 
      suggested that dapagliflozin, in combination with metformin, would be a 
      cost-effective alternative in the Spanish context for the treatment of T2DM.
CI  - Copyright (c) 2014 Elsevier Espana, S.L.U. All rights reserved.
FAU - Abad Paniagua, Eduardo Jose
AU  - Abad Paniagua EJ
AD  - Centro de Salud Las Aguilas, Madrid, Espana.
FAU - Casado Escribano, Pedro
AU  - Casado Escribano P
AD  - Hospital La Princesa, Madrid, Espana.
FAU - Fernandez Rodriguez, Jose Maria
AU  - Fernandez Rodriguez JM
AD  - Hospital Carmen y Severo Ochoa, Cangas de Narcea, Asturias, Espana.
FAU - Morales Escobar, Francisco J
AU  - Morales Escobar FJ
AD  - Centro de Salud de Arucas, Arucas, Gran Canaria, Espana.
FAU - Betegon Nicolas, Lourdes
AU  - Betegon Nicolas L
AD  - Departamento de Economia de la Salud Bristol-Myers Squibb, Madrid, Espana.
FAU - Sanchez-Covisa, Joaquin
AU  - Sanchez-Covisa J
AD  - Departamento de Economia de la Salud AstraZeneca, Madrid, Espana.
FAU - Brosa, Max
AU  - Brosa M
AD  - Oblikue Consulting, Barcelona, Espana. Electronic address: max.brosa@oblikue.com.
LA  - spa
PT  - Journal Article
TT  - Analisis de coste-efectividad de dapagliflozina en comparacion con los 
      inhibidores de la DPP4 y otros antidiabeticos orales en el tratamiento de la 
      diabetes mellitus tipo 2 en Espana.
DEP - 20141230
PL  - Spain
TA  - Aten Primaria
JT  - Atencion primaria
JID - 9111075
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 1ULL0QJ8UC (dapagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/*economics/therapeutic use
MH  - Cost-Benefit Analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*economics/therapeutic use
MH  - Glucosides/*economics/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*economics/therapeutic use
MH  - Models, Econometric
MH  - Spain
PMC - PMC6983792
OTO - NOTNLM
OT  - Costes
OT  - Costs
OT  - DPP4 inhibitors
OT  - Dapagliflozin
OT  - Dapagliflozina
OT  - Diabetes
OT  - Inhibidores de DPP4
OT  - Sulfonilureas
OT  - Sulphonylureas
OT  - Thiazolidinediones
OT  - Tiazolidindionas
EDAT- 2015/01/04 06:00
MHDA- 2017/09/07 06:00
PMCR- 2014/12/30
CRDT- 2015/01/04 06:00
PHST- 2014/04/23 00:00 [received]
PHST- 2014/10/29 00:00 [revised]
PHST- 2014/11/04 00:00 [accepted]
PHST- 2015/01/04 06:00 [entrez]
PHST- 2015/01/04 06:00 [pubmed]
PHST- 2017/09/07 06:00 [medline]
PHST- 2014/12/30 00:00 [pmc-release]
AID - S0212-6567(14)00390-4 [pii]
AID - 10.1016/j.aprim.2014.11.002 [doi]
PST - ppublish
SO  - Aten Primaria. 2015 Oct;47(8):505-13. doi: 10.1016/j.aprim.2014.11.002. Epub 2014 
      Dec 30.